GE HealthCare (GEHC) Technologies announced that it received notice on March 30, 2026, of an unsolicited “mini-tender” offer by Potemkin Limited to purchase up to 100,000 shares of GE HealthCare common stock at a price of $45.80 per share in cash. Potemkin Limited’s offer price of $45.80 per share is approximately 34.80 percent lower than the $70.25 closing per share price of GE HealthCare’s common stock on March 18, 2026, the last trading day before the mini-tender offer appears to have commenced. GE HealthCare does not endorse Potemkin Limited’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to Potemkin Limited’s offer because the offer is at a price that is significantly below the current market price for GE HealthCare’s common stock and subject to numerous conditions. For example, under the terms of Potemkin Limited’s offer, there could be a significant delay between the time that stockholders tender their shares and when stockholders will receive payment, and there are limits on the ability of tendering stockholders to withdraw their shares from the offer. GE HealthCare is not affiliated or associated in any way with Potemkin Limited, its mini-tender offer or its offer documentation, and GE HealthCare is not responsible for any obligations of the offer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 29
- GE HealthCare announces industrial role in new COMPASS consortium
- GE HealthCare to showcase cardiology portfolio at ACC.26
- GE HealthCare receives FDA clearance for Photonova Spectra
- Buy Rating on GE Healthcare: Resilient Omnipaque Franchise, Priced-in Competition, and Valuation Upside to $91 Target
